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Summary
Cardiac ischaemia and reperfusion leads to irreversible injury and sub-
sequent tissue remodelling. Initial reperfusion seems to shift arginine 
metabolism from nitric oxide (NO) to polyamine formation. This may 
limit functional recovery at reperfusion. The hypothesis was tested 
whether ischaemia/reperfusion translates such a shift in arginine me-
tabolism in a tumour necrosis factor (TNF)-α-dependent way and 
renin-angiotensin system (RAS)-dependent way into a sustained ef-
fect. Both, the early post-ischaemic recovery and molecular adap-
tation to ischaemia/reperfusion were analysed in saline perfused rat 
hearts undergoing global no-flow ischaemia and reperfusion. Local 
TNF-α activation was blocked by inhibition of TNF-α sheddase 
ADAM17. To interfere with RAS captopril was administered. Arginase 
was inhibited by administration of Nor-NOHA. Long-term effects of 
ischemia/reperfusion on arginine metabolism were analysed in vivo in 
rats receiving an established ischaemia/reperfusion protocol in the 
closed chest mode. mRNA expression analysis indicated a shift in the 
arginine metabolism from NO formation to polyamine metabolism 
starting within 2 hours (h) of reperfusion and translated into protein 
expression within 24 h. Inhibition of the TNF-α pathway and captopril 
attenuated these delayed effects on post-ischaemic recovery. This shift 
in arginine metabolism was associated with functional impairment of 
hearts within 24 h. Inhibition of arginase but not that of TNF-α and 
RAS pathways improved functional recovery immediately. However, 
no benefit was observed after four months. In conclusion, this study 
identified TNF-α and RAS to be responsible for depressed cardiac func-
tion that occurred a few hours after reperfusion.
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Introduction
The acute coronary syndrome is one of the leading causes for the 
development and progression to heart failure (1, 2). It can be suc-
cessfully treated by reperfusion strategies thereby limiting myo-
cardial damage but yet leading to new onset of heart failure. There-
fore, a better understanding of the molecular processes in the rep-
erfused post-ischaemic heart is required to improve pharmaco-
logical options that prevent the progression of cardiac remodelling 
to heart failure under such conditions.
Inhibition of the angiotensin converting enzyme (ACE) can 
positively affect post infarct remodelling specifically if treatment is 
started after a successful revascularisation. Delayed but not im-
mediate captopril therapy improved cardiac function and in-
creased survival (3–7). This suggests that the renin-angiotensin 
system (RAS) contributes to early post-infarct remodelling leading 
to progression to heart failure but not to direct reperfusion-linked 
injury. The molecular mechanisms that may explain such a behav-
iour of ACE inhibition in this specific setting are not clear. In an 
experimental study, captopril improved the bioavailability of nitric 
oxide (NO) after ischaemia/reperfusion if administered together 
with arginine (8). This suggests that in the post-ischaemic heart 
arginine may not be used by nitric oxide synthases (NOS) but by 
alternative pathways.
In general, an activation of NO-dependent cGMP-linked path-
ways is considered to improve the early post-ischaemic recovery 
(9). However, the post-ischaemic myocardium has a characteristic 
loss of NO-dependent signalling (10, 11). This is mainly due to an 
increased oxidative stress and diminished NO formation rather 
than the impaired downstream signalling of NO, because adminis-
tration of NO donors restores a normal NO-dependent signalling 
(12). Interestingly, chronic ischaemia leads to endothelial dysfunc-
tion in the heart that is independent of arginase activity (13). 
Therefore, the observed shift in arginine metabolism is specific for 
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ischaemia/reperfusion injury. Possible reasons for such a lack of 
responsiveness are either a down-regulation of NO forming path-
ways or an activation of pathways that compete with NO 
formation for the same substrates.
Arginine is also the substrate for the polyamine metabolism, a 
major pathway used for cell growth and differentiation (14, 15). In 
the polyamine metabolism, arginine is converted by arginases into 
urea and ornithine that is further decarboxylated by ornithine de-
carboxylase (ODC), the rate limiting enzyme of the polyamine 
metabolism. The polyamine metabolism has been shown to play a 
crucial role in myocardial adaptation and transition to heart fail-
ure in the chronic pressure overloaded heart (16). Furthermore, 
the induction of the polyamine metabolism is linked to the acti-
vation of the RAS (17). An activation of arginase-1 in post-is-
chaemic hearts seems to indicate an activation of the polyamine 
metabolism (18).
The current study tested the hypothesis that events related to is-
chaemia/reperfusion may trigger a shift of the arginine metab-
olism from NO formation to polyamine metabolism and was 
aimed to identify potential mechanisms that trigger this event. A 
likely candidate may be a rapid release of local TNF-α by ischae-
mia-dependent activation of the sheddase” TNF-α converting 
enzyme” (TACE, also known as ADAM17) because TNF-α has 
been shown to induce the expression of arginase-1 and an acti-
vation of arginase-1 was shown in post-ischaemic rat hearts 
(19–22). If this hypothesis holds, inhibition of TNF-α release dur-
ing ischaemia should avoid an activation of the arginine/poly-
amine pathway. In order to address these questions we performed 
in vitro experiments on isolated perfused rat hearts that were ex-
posed to global no-flow ischaemia and reperfusion and added 
TAPI, an inhibitor of TNF-α release, during ischaemia. However, 
as pre-ischaemic TACE inhibition cannot be used in clinical prac-
tice we tested next, whether captopril can restore the pre-is-
chaemic balance between NO and polyamine metabolism by in-
duction of the NO pathway.
In order to test this hypothesis captopril, an ACE inhibitor, was 
added to the perfusate of saline perfused rat hearts 30 minutes 
(min) after the onset of reperfusion. It has previously been shown 
that administration of sulfhydryl group containing ACE inhibitors 
can reduce infarct size if administered prior to ischaemia (i. e. 
[23]). Once again, as pre-ischaemic administration of therapeutics 
is not practicable in ischaemia/reperfusion in the clinical setting, 
captopril was given during late reperfusion in the subsequent ex-
periments. Hearts were reperfused for 2 hours (h) and molecular 
markers of remodelling as well as the functional recovery were de-
termined. Finally, we tested the effect of arginase inhibition during 
the onset of reperfusion. Unlike the above mentioned effects on 
transcription, a shift in arginine / eNOS activity may also be 
caused by uncoupling of NOS. In this case, inhibition of arginase 
should directly normalize the relationship between both arginine 
consumers.
Material and methods
Animal models and animal handling
The investigation conforms to the directive 2010/63/EU of the 
European Parliament. Use of animals was registered at the Justus-
Liebig-University (registration-no.: 417-M). The experimental 
protocols were approved by the ethics committee for animal ex-
perimentation of the local authorities in Giessen, Germany and 
Szeged, Hungary.
Myocardial infarction and reperfusion was performed in the 
closed-chest model. To achieve this, rats were anaesthetised by in-
halation of isoflurane (induction: 5 %, maintenance: 2–3 %), intu-
bated and placed on a respirator during surgery to maintain venti-
lation. Before surgery, 0.03 mg/kg nalbuphin (Nalbuphin Orpha, 
AOP Orpha Pharmaceuticals, Vienna, Austria) was injected (i. p.). 
The adequacy of anaesthesia was monitored by electrocardio-
graphy and pulse rate. A suture was placed around the left anterior 
descending coronary artery and remained subcutaneously (24). At 
2 h after the wound closing, 0.03 mg/kg nalbuphin was repeated to 
alleviate postoperative pain. Seven days later, rats were anaesthe-
tised as before and the suture was mobilised, and the LAD was oc-
cluded for 30 min. The occlusion was monitored by electrocardio-
graphy (ST elevation). Thereafter, the occluder was opened again 
and the suture was cut and the skin was closed in one layer. Sham 
rats received the same protocol but the occluder was not mobilised 
after seven days. Rats that received captopril after ischaemia/rep-
erfusion received the ACE inhibitor captopril (300 mg/l) in tap 
water (accumulating to approximately 30 mg/kg*day).
Ex vivo analysis of cardiac function
In order to analyse the cardiac function ex vivo, rats were anaes-
thetised again by isoflurane and killed by cervical dislocation. 
Thereafter hearts were rapidly excised and the aorta was cannu-
lated for retrograde perfusion with a 16-gauge needle connected to 
a Langendorff perfusion system. Left ventricular function was de-
termined by insertion of a water filled balloon into the left ven-
tricle as described before (25). Hearts were paced during measure-
ments.
In vivo analysis of cardiac function
Transthoracic echocardiography was performed as described pre-
viously (26) under isoflurane anaesthesia (1.5 %) at 120 days after 
ischaemia/reperfusion. Briefly, two-dimensional and M-mode 
echocardiographic examinations were performed in accordance 
with the criteria of the American Society of Echocardiography 
with a Vivid 7 Dimension ultrasound system (General Electric 
Medical Systems) using a phased array 5.5–12 MHz transducer 
(10S probe). Data of three consecutive heart cycles were analysed 
(EchoPac Dimension software; General Electric Medical Systems) 
by an experienced investigator in a blinded manner. The mean 
values of three measurements were calculated and used for statisti-
cal evaluation. Functional parameters including left ventricular 
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ejection fraction (EF) and fractional shortening (FS) were calcu-
lated on four-chamber view images.
qRT-PCR
After removing the hearts from the Langendorff apparatus, the left 
ventricular tissue was carefully isolated and quickly frozen in fluid 
nitrogen. Tissue samples were prepared to analyse the steady-state 
mRNA levels of proteins of interest according to the previously de-
scribed method (25). Briefly, total RNA was isolated from the left 
ventricles using peqGoldTriFast (peqlab, Biotechnology GmbH, 
Erlangen, Germany) according to the manufacturer’s protocol. To 
remove genomic DNA contamination, isolated RNA samples were 
treated with 1 U DNase per mg RNA (Invitrogen, Karlsruhe, Ger-
many) for 15 min at 37°C. On µg of total RNA was used in 10 µl 
reaction to synthesise cDNA using superscript RNaseH reverse 
transcriptase (200 U/µg; Invitrogen) and oligo dTs (Roche, Mann-
heim, Germany) as primers. Reverse transcriptase reactions were 
performed for 60 min at 37°C. Real-time PCR was performed 
using the Icycler IQ detection system (Bio-Rad, Munich, Ger-
many) in combination with IQ SYBR Green real-time supermix 
(Bio-Rad). A complete list of all primers used in this study is given 
in ▶ Table 1. Data are normalised to hypoxanthine phosphoribo-
syltransferase (HPRT) expression that was used as a house-
keeping gene in this study. Preliminary experiments with β2 
microglobulin, which was alternatively considered as housekeep-
ing gene, revealed similar results but higher variability. The relative 
change in expression was quantified by the ΔΔCT method (27).
Western blots
Tissue samples from hearts stored at -80°C were used as described 
previously and prepared for standard SDS gel electrophoresis. Pro-
tein was extracted as described before (25). The lysis buffer con-
tained (mmol/l): Tris-HCl (pH 7.5) 20, NaCl 150, EGTA 1, EDTA 
2, Triton (1 % v/v), sodium pyrophosphate (2.5), β-glycerophos-
phate 1, Na3VO4 1, leupeptin (1 µg/ml) (Cell Signalling Technol-
ogy, Leiden, Netherland). The homogenate was centrifuged at 
1,000 g at 4°C for 10 min and the supernatant was used for protein 
detection by Western blotting. Supernatants were treated with 
Laemmli buffer (reducing conditions with β-mercaptoethanol; 
non-reducing conditions without β-mercaptoethanol). Samples 
were subsequently heated for 5 min at 95°C (reducing conditions) 
or incubated for 30 min at room temperature (non-reducing con-
ditions). Protein samples were loaded on NuPAGE Bis-Tris Precast 
gels (10 %; Life Technology, Darmstadt, Germany) and subse-
quently transferred onto nitrocellulose membranes. Primary anti-
bodies directed against eNOS , ODC, and cardiac α-actin (loading 
control) were used as described before (27). Tropomyosin blots 
were incubated with an anti-tropomyosin antibody purchased 
from Sigma-Aldrich (Taufkirchen, Germany; product T9283). The 
antibody was previously used to establish tropomyosin disulphide 
cross-bridging (29).
Measurement of superoxide
To perform DHE staining, cryosections of left ventricles were in-
cubated with DHE (dissolved in 1 X PBS) for 10 min at 37 °C in a 
light-protected humidity chamber, then fixed with Dako Fluor-
escent Mounting Medium (Dako, Glostrup, Denmark). Slides were 
then imaged by confocal microscopy (LSM 510 META; Carl Zeiss, 
Jena, Germany) using an excitation wavelength of 488 nm; 
emission was recorded at 540 nm. Assessment was performed by 
digital image analysis using Leica Confocal Software Lite Version 
(LCS Lite). The mean fluorescence intensity of n=8 per group was 
used to quantify the extent of superoxide.
Quantification of TNF-α concentrations
Langendorff heart-perfusates were collected prior to ischaemia 
and one minute after reperfusion and filtered through 0.2 µm filter 
to remove any residual debris. To quantify the TNF-α production, 
an enzyme-linked immunosorbent assay (ELISA) (Quantikine®, 
R&D Systems, Minneapolis, MN, USA) was used. Absorbance 
values for individual reactions were determined using VersaMax™ 
Microplate Reader with SoftmaxPro 3.0 data processing software.
Statistics
The results are expressed as means ± S. E. M. or box plots as indi-
cated in the legend to the figures. Statistical comparisons were per-
formed by two-side ANOVA and Student-Newman-Keuls post-
hoc analysis. Levene test was used to check the normal distribution 
Table 1: RNA primer 
sequences.
HPRT
eNOS
ODC
Arginase-1
Arginase-2
ANP
SERCA2a
Bax
Forward
CCA GCG TCG TGA TTA GTG AT
AGC CCG GGA CTT CAT CAA TCA
GAA GAT GAG TCA AAC GAG CA
GGA AGC ATC TCT GGC CAC GCC
TGA GGA GCA GCG TCT CCC GT
ATG GGC TCC TCC TCC ATC AC
CGA GTT GAA CCT TCC CAC AA
ACT AAA GTG CCC GAG CTG ATC CAC
Reverse
CAA GTC TTT CAG TCC TGT CC
GCC CCA AAC ACC AGC TCA CTC TC
AGT AGA TGT TTG GCC TCT GG
CAC CGG TTG CCC GTG CAG
GCT TCT CGG ATG GCG GCT GG
TCT TCG GTA CCG GAA GCT
AGG AGA TGA GGT AGC GGA TGA A
TGT CTG CCA TGT GGG G
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of the samples. A p-value of 0.05 was considered as statistical sig-
nificant.
Results
Influence of TAPI administration during ischaemia  
on the functional recovery of post-ischaemic hearts 
and the expression of genes linked to arginine 
 metabolism
In the first set of experiments we tested the hypothesis that TNF-α 
released during ischaemia may trigger a molecular switch of argi-
nine metabolism during reperfusion by an activation of the shed-
dase “TNF-α converting enzyme” (TACE). In order to address this 
question we administered the TACE inhibitor TAPI (1 µM) to 
hearts prior to the onset of ischaemia. ▶ Figure 1 describes the 
subsequent changes in mRNA expression of arginase-1, eNOS, or-
nithine decarboxylase (ODC), and the ratio between eNOS and 
ODC. Ischaemia/reperfusion increased arginase-1 mRNA ex-
pression, whereas a decreased mRNA expression of eNOS and in-
creased mRNA expression of ODC shifted the eNOS/ODC ratio 
into the direction of polyamine metabolism. Noteworthy, all these 
changes were completely attenuated if TAPI was administered 
prior to reperfusion. However, these molecular changes on mRNA 
expression had no effects on the functional heart recovery within 2 
h. At 2 h after reperfusion, hearts developed a mean left ventricu-
lar pressure of 59.4 ± 8.9 mmHg in control hearts and 63.4 ± 5.8 
mmHg in hearts treated with TAPI (p=0.717, n=6). Pre-ischaemic 
values had been 95.1 ± 2.6 mmHg and 96.2 ± 6.3 mmHg, respect-
ively. As expected, TAPI significantly attenuated the release of 
TNF-α into the perfusate. This amount of TNF-α was 13.0 ± 4.3 
pg/ml in the perfusate of normoxic control hearts and increased to 
52.5 ± 10.9 pg/ml (p< 0.05; n=6 hearts) in the perfusate of post-is-
chaemic hearts. TAPI reduced this increase to 19.6 ± 9.8 pg/ml. 
Collectively these data show that ischaemia/reperfusion shifts the 
arginine pathway into the direction of polyamine metabolism and 
identify TNF-α as a causative factor in this process. Whether this 
process can be reversed by inhibition of the local RAS was tested 
next.
Functional recovery of rat hearts after ischaemia/ -
reperfusion and influence of captopril
In order to address the question whether ACE inhibition can an-
tagonise TNF-α-driven molecular changes of ischaemia/reperfu-
sion, the ACE inhibitor captopril was added 30 min after the onset 
of reperfusion. Again, there were no functional differences be-
tween the treatment group and the captopril group. Pre-ischaemic 
values of left ventricular developed pressure (LVDP) were 115.3 ± 
6.1 mmHg and 104.9 ± 6.6 mmHg. At 30 min after the onset of 
reperfusion and before starting captopril administration LVDP 
values were 85.9 ± 10.6 mmHg and 85.4 ± 5.3 mmHg, respectively. 
Finally, LVDP values amounted to 50.5 ± 5.2 mmHg and 48.0 ± 5.7 
mmHg, respectively, 2 h after the start of reperfusion. Thus, capto-
pril did not affect the functional recovery of hearts when adminis-
tered 30 min after reperfusion and present for further 90 min.
Figure 1: Left ventricu-
lar mRNA expression 
of arginase 1, eNOS, 
ODC and the ODC-to-
eNOS ratio in hearts 
exposed to 45 min is-
chaemia and 120 min 
reperfusion. HPRT was 
used to normalise the 
data. Data are shown as 
box plots and individual 
data points outside the 
5 % and 95 % are indi-
cated separately. The 
dashed line indicates 
basal expression of con-
trol hearts (Nx) not 
undergoing 45 min of is-
chaemia and reperfusion 
(I/R). TAPI (1 µmol/l) was 
used to inhibit the activity 
of TACE. *, p< 0.05 vs Nx 
(n=6–8 hearts).
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Figure 2: Left ventricular mRNA expression of arginase 1, eNOS, ODC 
and the ODC-to-eNOS ratio in hearts exposed to 45 min ischaemia 
and 120 min reperfusion. HPRT was used to normalise the data. Data are 
shown as box plots and individual data points outside the 5 % and 95 % are 
indicated separately. The dashed line indicates basal expression of control 
hearts (I/R) not receiving captopril (100 µmol/l) starting 30 min after the 
onset of reperfusion. Exact p-values are given (each n=8).
In contrast to the lack of effect on functional recovery, a clear 
trend to higher expression of eNOS following captopril was found. 
Moreover, the mRNA expression of arginase-1 and ODC was 
lower than in the non-treatment group (▶ Figure 2). Collectively, 
these data show that inhibition of the local ACE system potentially 
attenuates the shift of the arginine metabolism by up-regulation of 
eNOS. The data in the in vitro model show significant effects on 
the mRNA expression of enzymes involved in the arginine metab-
olism. However, these changes seem not to be functionally relevant 
within minutes because these changes have to be translated into 
proteins first. Whether this shift in arginine metabolism modifies 
the outcome at later time points was investigated next in an appro-
priate in vivo model.
Functional recovery of rats after in vivo ischaemia/
reperfusion and effect of administration of captopril
In order to address the functional relevance of eNOS up-regu-
lation by captopril, rats underwent ischaemia and reperfusion in 
the so-called closed chest model. Rats received either captopril 
with their tap water directly after recovery from the surgery for 
one or three days (treatment group) or no drug (non-treatment 
group). Control rats underwent sham surgery without ligation of 
the left anterior descending artery. Cardiac function was analysed 
ex vivo in saline perfused rat hearts. Post-ischaemic rats developed 
a loss of cardiac function at day 1 after reperfusion that was less 
pronounced at day 3 after reperfusion (▶ Table 2). Of note, this 
early loss of function was largely attenuated in the captopril group. 
When the mRNA expression of eNOS, arginase-1 and ODC was 
analysed in post-ischaemic hearts from rats of the control group in 
comparison to the captopril group, they displayed significant dif-
ferences. As indicated in ▶ Figure 3, the administration of the 
ACE inhibitor induced down-regulation of the mRNA expression 
of ODC and normalised the expression of eNOS. On the protein 
level, ODC mRNA expression was higher in post-ischaemic non-
treated hearts, and the inhibitor attenuated the induction of ODC. 
It also normalised the expression of eNOS and the ODC-to-eNOS 
ratio.
The differences between treated and non-treated rats in left 
ventricular function were lower at day 3 (▶ Table 2) and at that 
time-point the molecular adaptations were also smaller compared 
to day 1 but all changes displayed a similar trend than at day 1 
(▶ Figure 4). In addition, the induction of arginase-1 by ischae-
mia/reperfusion remained significant at day 1 after reperfusion 
but was again normalised by captopril administration (▶ Figure 
5). This effect of ischaemia/reperfusion on arginase expression was 
lost within the subsequent days (▶ Figure 5). In summary, capto-
pril shifted the arginine metabolism into the direction of NO me-
tabolism. This effect was induced at a very early time point as seen 
in the saline perfused rat hearts (see above, although not function-
ally significant at this time point), strongest at day 1 after reperfu-
sion, but already beginning to be lost within the next days in the 
presence of captopril.
Mechanistically the question occurred whether the attenuation 
of the shift in arginine metabolism may cause decreased oxidative 
stress. As expected, ischaemia/reperfusion caused an increase in 
superoxide formation as indicated by increased DHE staining 
(Suppl. Figure 1a, b, available online at www.thrombosis-online.
com). As recently demonstrated, oxidative modification of trop-
omyosin leads to myocardial dysfunction by TNF-α-dependent in-
Day 1 (24 h)
Sham
I/R
Δ
Sham / Capto
I/R / Capto
Δ
Day 3 (72 h)
Sham
I/R
Δ
Sham / Capto
I/R / Capto
Δ
Data are means S.E.M. from n=8 hearts each.  
*p<0.05 vs. Sham. 
LVDP (mmHg)
158 ± 7
123 ± 7
-35*
186 ± 11
165 ± 5
-21
155 ± 8
132 ± 10
-23
168 ± 8
153 ± 8
-15
LVDP (%)
100 ± 4
78 ± 4
-22*
100 ± 6
89 ± 2
-11
100 ± 5
85 ± 7
-15
100 ± 5
91 ± 5
-9
Table 2: Effect of captopril on cardiac function ex vivo 24 and 72 
hours after ischemia/reperfusion.
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duced oxidative stress. As shown in Suppl. Figure 1c (available on-
line at www.thrombosis-online.com), under non-reducing condi-
tions the anti-tropomyosin antibody detected a band at approxi-
mately 45 kDa corresponding to a band detected under reducing 
conditions as well, and an additional band at a much higher mo-
lecular weight appeared (approximately at 80 kDa), which most 
likely was caused by disulphide cross-bridges (DCB; [29]). Ischae-
mia/reperfusion resulted in a higher degree of DCB amounts and 
this was no longer significantly enhanced if captopril was adminis-
tered during the first day (Suppl. Figure 1c, available online at 
www.thrombosis-online.com).
Figure 3: Protein and 
mRNA expression of 
eNOS and ODC in rat 
hearts from rats under-
going 30 min of is-
chaemia and 24 h of 
reperfusion in vivo. 
Where indicated, rats re-
ceived captopril by tap-
water after surgery. Data 
are shown as box plots 
and individual data points 
outside the 5 % and 95 % 
are indicated separately. 
The dashed line indicates 
basal expression of con-
trol hearts (Sham) not re-
ceiving captopril. Exact 
p-values are given (each 
n=8).
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Functional recovery of rats after in vitro ischaemia/
reperfusion and effect of administration of Nor-NOHA
The results shown above have clearly shown the impact of argi-
nase/ODC and eNOS expression on post-ischaemic recovery 
within 24 h. Without changes in expression, a similar shift may 
occur at the onset of reperfusion due to eNOS uncoupling (see In-
troduction). Whether an increased activity of arginase relative to 
eNOS can contribute to oxidative stress, namely superoxide 
formation, and directly depress functional recovery was investi-
gated next. To address this question, arginase activity was in-
hibited by Nor-NOHA, a specific inhibitor of arginase during rep-
Figure 4: Protein and 
mRNA expression of 
eNOS and ODC in rat 
hearts from rats under-
going 30 min of is-
chaemia and 72 h of 
reperfusion in vivo. 
Where indicated, rats re-
ceived captopril by tap-
water after surgery. Data 
are shown as box plots 
and individual data points 
outside the 5 % and 95 % 
are indicated separately. 
The dashed line indicates 
basal expression of con-
trol hearts (Sham) not re-
ceiving captopril. Exact 
p-values are given (each 
n=8).
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erfusion. As expected, ischaemia/reperfusion caused an increase in 
superoxide formartion as indicated by increased DHE staining 
(▶ Figure 6 A, B). However, inhibition of arginase activity during 
reperfusion caused a significant reduction of oxidative stress and 
improved the functional recovery of these hearts (▶ Figure 6 A, B). 
This increased oxidative stress went along with a clear shift in 
tropomyosin oxidation (▶ Figure 6 C). In addition, the functional 
recovery (120 min reperfusion) was significantly improved in 
hearts that received Nor-NOHA at the onset of reperfusion 
[LVDP: 57.4 ± 9.2 mmHg (Nor-NOHA; n=8) vs 44.1 ± 9.2 mmHg 
(Control; n=11); p< 0.05]. Pre-ischaemic values were 116.4 ± 20.5 
and 121.1 ± 20.4 mmHg, respectively. These data suggest that the 
shift in arginine metabolism is associated with changes in the ox-
idative stress affecting directly the cardiac function. Collectively 
the data suggest that activation of the local TNF-α system convert 
the acute activation of arginase into sustained arginase activation 
by transcriptional activation and that this process can be attenu-
ated by induction of the counter-regulatory eNOS by ACE in-
hibition.
Long-term effect of the captopril-driven attenuation 
of the shift in arginine metabolism in the early phase 
of reperfusion
Finally, we examined whether this early protection by captopril has 
any long-term consequences for the post-ischaemic recovery. At 
day 120, no differences in the mRNA expression of molecules 
linked to arginine metabolisms (eNOS, arginase-1, ODC) were 
found between both groups of ischaemia/reperfusion (Suppl. Fig-
ure 2, available online at www.thrombosis-online.com). Surpris-
ingly, although captopril treatment had a significant better func-
tional recovery of the heart during the first days after reperfusion 
in vivo, this did not end up in any functional improvements after 
four months. This was indicated in vivo by a similar reduction of 
EF compared to sham rats in treated and non-treated rats, and 
confirmed in vitro by a lower LVDP in saline reperfused rat hearts. 
However, although no functional effect was found in these rats 
three molecular markers of cardiac hypertrophy and remodelling 
showed significant difference in their mRNA expression between 
captopril-treated and non-treated rats. These were ANP, a marker 
of cardiac hypertrophy that was elevated in the captopril group, 
SERCA2a, a calcium transporter that improves cardiac function by 
Figure 5: Left ventricu-
lar mRNA expression 
in rat hearts from rats 
undergoing 30 min of 
ischaemia and 24 h 
(A,B) or 72 h (C,D) of 
reperfusion in vivo. 
Data are shown as box 
plots and individual data 
points outside the 5 % 
and 95 % are indicated 
separately. The dashed 
line indicates basal ex-
pression of control hearts 
(Sham) not receiving cap-
topril. Exact p-values are 
given (each n=8).
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acceleration of calcium refilling of the sarcoplasmatic reticulum 
that was also higher expressed in the captopril group, and bax, a 
pro-apoptotic factor, which was less expressed in these rats (▶ Fig-
ure 7). These changes suggest a slightly different type of compen-
satory hypertrophy in captopril-treated rats.
Discussion
This study demonstrated that at the onset of reperfusion and sev-
eral hours after reperfusion a shift within the arginine metabolism 
occurs that favours arginine consumption into the polyamine me-
tabolism and reduces NO formation. Initially, this shift is triggered 
by eNOS uncoupling. Inhibition of arginase normalises the ratio 
between the activities of both arginine consumers and thereby re-
duces oxidative stress. This shift in arginine metabolism is main-
tained at later time points by an induction of arginase-1 and ODC 
mRNA and protein expression and a down-regulation of eNOS 
mRNA expression. As a potential mechanism that triggers this 
transcriptional activation, we identified ischaemia/reperfusion-de-
pendent activation of TACE. As a new finding of this study we 
show for the first time that this shift in arginine metabolism can be 
normalised by inhibition of the cardiac RAS. This inhibition at-
tenuates the down-regulation of eNOS. Under these conditions, 
cardiac function was maintained at day 1 after reperfusion. Mech-
anistically, it is suggested that NO as a radical acceptor binds ROS 
that would otherwise oxidise cysteine residues at tropomyosin and 
thereby reduce cardiac function. In this study we show that in-
hibition of arginase during reperfusion indeed reduces superoxide 
formation and improves the early functional recovery and that in-
terference with arginase up-regulation and eNOS down-regulation 
improves the situation within hours. Despite these promising re-
sults the long-term cardioprotective effect is low in terms of func-
tional aspects but is associated with moderate molecular adap-
tations on the mRNA expression level. A schematic overview 
about the proposed mechanism is given in ▶ Figure 8.
It has previously been shown that ischaemia leads to an induc-
tion of arginase-1 that converts arginine into ornithine so that ar-
ginine is no longer available as a substrate of eNOS. At least in the 
rat arginase-1 is the main isoform (18). Our study confirmed these 
findings and documented that within minutes after reperfusion ar-
gininase-1 mRNA expression increases in isolated saline perfused 
Figure 6: Superoxide 
formation in post-is-
chaemic hearts and its 
modification by argi-
nase inhibition. Data 
are shown for control 
hearts (normoxic perfu-
sion), post-ischaemic 
hearts (30 min after rep-
erfusion; I/R), and hearts 
receiving the arginase in-
hibitor Nor-NOHA (100 
µM) during reperfusion. 
A) Representative tissue 
slices with superoxide 
staining by DHE in green. 
B) Quantitative analysis 
of DHE staining for the 
three groups (each n=8). 
*, p< 0.000 vs control 
and Nor-NOHA group. C) 
Representative immuno -
blots of tropomyosin 
under non-reducing con-
ditions.
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rat hearts its protein expression is increased 24 h after ischaemia/
reperfusion in vivo. Furthermore, although it is unlikely that an in-
duction of arginase expression leads to a functional active enzyme 
within minutes our data show that we can attenuate the formation 
of oxidiative stress by inhibition of arginase. The most likely expla-
nation for these acute effects are eNOS uncoupling at the time of 
reperfusion (10, 11). Our finding that arginase-1 is strongly in-
duced in vitro suggests that local mechanisms may trigger this in-
crease. Arginase is known to be induced by TNF-α (22). In the 
context of ischaemia/reperfusion, local release of TNF-α triggered 
by TACE may induce this response. We hypothesised that TACE 
will be activated by ischaemic events and liberates TNF-α because 
it is reasonable to assume that necrotic cell death during ischaemia 
will lead to the release of cellular components like RNA that subse-
quently may activate TACE (19). Indeed, an inhibition of TACE 
blocked reduced TNF-α concentration in the perfusate and attenu-
ated arginase-1 induction.
Figure 7: Left ventricular mRNA expression of ANP, SERCA2a, and 
bax in hearts exposed to 30 min ischaemia and 120 days of reperfu-
sion. HPRT was used to normalise the data. Data are shown as box plots and 
individual data points outside the 5 % and 95 % are indicated separately. The 
dashed line indicates basal expression of control hearts (Sham) not receiving 
captopril. *, p< 0.05 vs Sham (each n=8).
Figure 8: Summary figure - Ischaemia/Reperfusion (I/R) uncouples 
eNOS and thereby shifts the relationship between arginase / ODC 
and eNOS into the direction of arginase. This causes oxidative stress, ox-
idation of tropomyosin and loss of function. Inhibition of arginase (red la-
belled No. 1) normalised the relationship between arginase and eNOS. I/R 
also led to release of cell compounds due to loss of sarcolemmal integrity in-
cluding RNA. Extracellular RNA (eRNA) activates TACE leading to liberation 
of bound TNF-α. TNF-α induces the expression of arginase and ODC and acti-
vates the renin-angiotensin-system (RAS) that down-regulated the ex-
pression of eNOS. The subsequent unbalance between arginase / ODC and 
eNOS causes again oxidative stress, oxidises tropomoysin, and reduces func-
tion. Please note the time scale. Liberation of TNF-α can be attenuated by in-
hibition of TACE (red labelled 2), RAS can be attenuated by captopril (red la-
belled 3). Inhibition of arginase has acute effects, inhibition of TACE or RAS 
delayed effects.
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Although induction of arginase-1 may already indicate a shift 
of the arginine metabolism into the direction of the polyamine 
metabolism, the rate limiting enzyme of the polyamine metab-
olism is not arginase-1 but ODC. Of note, based on the analysis of 
arginase knockout mice, arginase expression and activity seems 
not to affect polyamine metabolism directly at least in healthy 
mice underlining the importance of ODC expression in the induc-
tion of polyamine metabolism (30). Interestingly, in the setting of 
cardiac ischaemia/reperfusion arginase-1 and ODC were co-in-
duced in vitro. In the in vivo model protein expression of ODC was 
higher 24 h after the onset of reperfusion, although only at a bor-
derline level of significance (p=0.051). Nevertheless, these data 
suggest that the induction of the polyamine metabolism in post-is-
chaemic hearts includes ODC.
From these experiments the question arises how TNF-α may 
trigger these changes with an adverse outcome. It is well known 
that an inhibition of the local RAS in post-infarct models improves 
the post-ischaemic heart recovery at least in a certain time window 
(see Introduction). Can it be that TNF-α activates a local RAS that 
then triggers the shift into the polyamine metabolism? Evidence 
for this hypothesis comes from experiments with transgenic mice 
with a restricted overexpression of TNF-α in the heart. These mice 
displayed an activation of the cardiac-specific RAS (31). Combin-
ing both findings, TNF-α may indeed activate a local RAS that 
then triggers the shift in the polyamine metabolism. Inhibition of 
the local RAS 30 min after the onset of reperfusion in the in vitro 
system induced eNOS expression and increased the eNOS-to-
ODC ratio on the level of mRNA expression. This was not accom-
panied by a rapid functional improvement at that time. However, 
one cannot expect such an effect within 90 min after treatment be-
cause this may be too early for changes on the protein expression 
level. ACE inhibition significantly preserved the function com-
pared to non-treated rats in vivo, although treatment was started 
late after reperfusion. The timing of the start of captopril treat-
ment was based on previous findings that earlier treatment is not 
successful and excludes any effect on infarct size that is established 
within minutes after reperfusion (3). Of note, this treatment re-
gime led to a normalisation of eNOS expression and moderate ef-
fects on arginase-1 and ODC expression as well. These promising 
effects were lost during the following days even in the presence of 
the ACE inhibitor. Collectively our data show a significant con-
tribution of local RAS to the arginine switch that has functional 
consequences during the first days after reperfusion.
So far the data indicated that the post-ischaemic shift of the ar-
ginine metabolism is initiated by ischaemia-dependent activation 
of TNF-α, that then triggers an activation of the RAS. The final 
question to answer is, however, whether this leads to a long-term 
protection against the transition of the pre-ischaemic healthy heart 
into post-ischaemic heart failure. The closed chest model limits 
any inflammation linked to the experimental procedure and limits 
inflammation to the infarct healing-related aspects. This allowed 
to follow-up the animals for longer time periods up to four 
months. As expected, post-ischaemic rats developed a reduced 
cardiac function as shown by echocardiography. However, even 
rats that previously received the ACE inhibitor during the first 
seven days after reperfusion, in which wound healing and remod-
elling starts, still developed signs of heart failure. There was no 
functional difference between both groups after four months. 
Nevertheless, the left ventricular mRNA expression of ANP and 
SERCA2a were highest in these rats whereas the expression of the 
pro-apoptotic bax was lowest. Interestingly, we have previously 
shown that putrescine activates bax expression immediately after 
reperfusion, while inhibition of ODC activity reduced the bax ex-
pression (32). Collectively the data suggest that polyamines can af-
fect bax mRNA expression and that ACE inhibition attenuates this 
effect. Any speculation about the contribution of altered bax 
mRNA expression on the rate of apoptosis, however, cannot be 
drawn from this study. Nevertheless, the data underline an effect 
of temporary ACE inhibition on post-infarct remodelling. The 
long-term functional consequences cannot be predicted at the 
present state and require further studies.
The aforementioned changes in cardiac expression of enzymes 
of the arginine metabolism in vivo are not due to changes in differ-
ences in infarct sizes as treatment stared at earliest 30 min after 
reperfusion, a time at which infarct size has already been estab-
lished (see above). In the in vitro experiments performed here, in-
farct sizes can also not be impaired in the captopril experiments. 
In case of TACE and arginase inhibitors had to be given at earlier 
time points because their activity is critically involved at earlier 
time points. However, based on protein leakage from perfused rat 
hearts there was no difference in infarct sizes (data not shown). 
Collectively the data show that arginase metabolism can be modi-
fied independent of infarct sizes.
As mentioned above, timing of drug administration and type of 
linkage of ROS to tropomyosin oxidation suggest that the manipu-
lation of arginine metabolism are direct consequences of ROS 
scavenging rather than consequences of cell death. The data are 
also consistent with the assumption that some of the cardiac de-
pressive mechanisms at the early post-ischaemic period are tran-
sient effects as those shown in this study.
In summary, the current study describes new mechanisms how 
ischaemia/reperfusion leads to a shift in arginine metabolism dur-
ing the early phase of reperfusion, how this can be attenuated and 
that this improves the early functional recovery. Importantly, the 
improved cardiac function observed during the initial phase after 
reperfusion indicates that this mechanism may significantly con-
tribute to the early reduction of cardiac function after myocardial 
infarction and reperfusion. The study also shows that this mech-
anism is not part of the subsequent remodelling process leading to 
heart failure in post-ischaemic hearts and that a better initial re-
covery does not attenuate this process either. However, the early 
phase after reperfusion is a critical phase in general and any im-
provement of cardiac function at this time will probably reduce 
post-reperfusion complications.
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